Polymer-Linked Insulin Conjugates for Graded, Reversible Glucose Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing glucose-responsive insulins lack reversibility and graded responsiveness to physiological glucose levels, often causing immune reactions and limited responsiveness due to macromolecular frameworks that hinder specific and proportionate insulin receptor binding.
Innovation Solution
A conjugate comprising an insulin molecule covalently linked with polymers, decoy ligands, and glucose-binding agents, allowing for reversible and graded responses to glucose concentrations by controlling insulin receptor binding through conformational changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lectin-based systems or albumin binding insulin analogues are used to achieve glucose-responsive insulin release, then insulin can be released in response to glucose, but reversibility is not easily achieved because insulin can be diluted and not captured back when insulin levels decrease
Solution Approach 1:
The system divides the glucose-responsive mechanism into separate functional components: a polymer backbone with glucose-binding moieties (such as boronate groups) that can reversibly bind glucose, and insulin-binding sites that remain available for insulin capture. This segmentation allows the glucose-responsive element to function independently without permanently sequestering insulin, enabling reversibility.
Solution Approach 2:
The patent introduces a polymer intermediary containing glucose-binding groups (such as boronate groups) that mediates between glucose and insulin. This intermediary can bind glucose reversibly and simultaneously present insulin-binding sites, allowing insulin to be captured and released in response to glucose levels without direct irreversible binding between insulin and glucose.
2Measurement precision
If lectins are used to achieve specificity towards glucose, then glucose binding specificity is improved, but immune reactions or mitogenic effects may occur requiring additional modifications
Solution Approach 1:
The patent replaces expensive and potentially harmful lectins with synthetic or biocompatible polymer-based glucose-binding moieties (such as boronate groups). These synthetic groups provide the necessary glucose specificity without the immune-reactive properties of lectins, effectively substituting a harmful biological component with a safer synthetic alternative.
Solution Approach 2:
The patent changes the chemical nature of the glucose-binding component from biological lectins to synthetic polymer groups with specific chemical properties (such as boronate-diols). This parameter change maintains glucose-binding specificity while eliminating the harmful immune and mitogenic effects associated with lectins.
3Device complexity
If a single affinity ligand is connected to the A-chain and a glucose binding receptor to the B-chain, then the structure is simplified, but the ability to have graded, proportionate and specific response to changes in glucose levels is limited
Solution Approach 1:
The patent merges multiple functional elements onto a single polymer structure: multiple glucose-binding moieties, multiple insulin-binding sites, and the polymer backbone itself. This consolidation allows the system to achieve graded responses through the collective behavior of multiple binding sites while maintaining structural organization.
Solution Approach 2:
The polymer structure serves multiple functions simultaneously: it provides structural support, contains glucose-binding moieties for glucose sensing, presents insulin-binding sites for insulin capture, and enables graded responses through variable stoichiometry. This multi-functionality allows a single structural element to replace what would otherwise require multiple separate components.
4Reliability
If macromolecular frameworks are used to control insulin activity, then insulin release can be controlled, but the frameworks are large and cannot be accommodated close to insulin while maintaining insulin receptor engagement
Solution Approach 1:
The patent transitions from large three-dimensional macromolecular frameworks to a more compact polymer structure that utilizes efficient spatial arrangement. The polymer chain folds and organizes to present binding sites in a compact configuration, reducing the overall volume while maintaining control functionality through the polymer's flexible chain structure.
Solution Approach 2:
The patent employs a flexible polymer chain structure that can adopt various conformations to present binding sites close to the insulin molecule. This flexible polymer structure replaces rigid macromolecular frameworks, allowing the binding elements to be positioned in close proximity to insulin while maintaining the necessary control functionality through the polymer's flexibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate provides a graded and reversible response to glucose levels, enhancing insulin receptor binding control and reducing immune reactions, thereby improving glucose level management.
Implementation Method 1
modified insulins that can non-covalently bind to albumin or diols in the body and be released upon binding to glucose
Implementation Method 2
allowing for reversible and graded responses to glucose concentrations by controlling insulin receptor binding through conformational changes
Implementation Method 3
provide a graded and reversible response to changes in glucose levels under physiological conditions
Data Source
AI summary
This disclosure provides a composition containing a conjugate with a modified insulin molecule. The conjugate has an insulin molecule, which can be insulin or an insulin analog, glucagon, GLP-1, GLP-2 or a GLP-I agonist. The conjugate also contains one or more polymers. Each of the one or more polymers is covalently linked to the insulin molecule. Additionally, each of the one or more polymers is covalently linked to between 0 to 50 copies of a decoy ligand, and to between 0 to 50 copies of a glucose-binding agent, such that the combined total number of glucose-binding agents and decoy ligands covalently linked to each of the one or more polymers is at least 1. The conjugate can reversibly bind to soluble glucose and in which the extent of its glucose-binding controls the extent to which the modified insulin is able to bind to and activate the insulin receptor. Methods of making the conjugate, as well as use of the conjugate in treatment, are also provided.